Is AZTA a Good Stock to Buy? The Bull and Bear Case (2026)

Last updated November 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for Azenta (AZTA) rests on Margin recovery from cost cuts: The plan for fiscal 2027 depends mainly on costs. The bear case rests on execution is the main risk. Analysts covering it publish targets from $50.00 to $57.00 against a $44.80 share price on November 20, 2026, so even the professionals disagree by 13% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

AZTA key stats

At $44.80 on November 20, 2026, Azenta (AZTA) has a market cap of $1.9B. It next reports earnings around February 3, 2027 (estimated).

Market cap
$1.9B
P/E (forward)
50.3
Price to book
1.3
Beta
1.47
Next earnings
around February 3, 2027 (estimated)

Market cap, P/E and yield are measured at the $44.80 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Azenta (AZTA)?

The last two weeks for Azenta, as of November 22, 2026: the price move, the next earnings date, and what analysts changed.

  • AZTA closed at $44.80 on November 20, 2026, down 1.9% over the past five trading days (from $45.65).
  • Azenta next reports quarterly results around February 3, 2027 (estimated).
  • On November 11, 2026, Jefferies raised its target to $52.00 from $44.00 (Buy).
  • On November 11, 2026, Needham raised its target to $57.00 from $37.00 (Buy).

Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Azenta, Inc., based in Burlington, Massachusetts, is what remains of Brooks Automation after it sold its semiconductor robotics business in 2022. It now has two segments. Sample Management Solutions (about $344 million of fiscal 2026 revenue) sells automated freezers and storage systems, cryogenic equipment, sample tubes and consumables, and runs repositories that store millions of biological samples for drug companies, biobanks and research groups. Multiomics (about $277 million) is GENEWIZ, which sells Sanger sequencing, next-generation sequencing and gene synthesis as a service. In July 2026 Azenta sold B Medical Systems, its vaccine cold-chain business, so it is now reported as discontinued. Fiscal 2026, which ended September 30, was a hard year. Revenue from continuing operations rose about 5% to ~$622 million, but only about 2% organically. In May the company took a ~$149 million goodwill impairment on Multiomics, cut its outlook, and reported rework costs in its Automated Stores freezer line; the stock fell about 25% in a day. In August CEO John Marotta resigned and director Dr. Martin Madaus became interim CEO. The year ended better. On November 10 Azenta reported fourth-quarter revenue of ~$167 million (up 5%) and adjusted EPS of $0.28 against consensus near $0.11 to $0.12, and guided fiscal 2027 revenue to ~$648 million to $660 million with 200 to 250 basis points of adjusted EBITDA margin expansion. The shares rose about 20% the next day, to roughly $48.90, and closed near $44.51 on November 20, up about 22% over the month. Needham raised its target to $57 from $37 and kept a Buy rating. The balance sheet is the steady part. Azenta ended the year with ~$506 million of cash and marketable securities and no debt, bought back 4.4 million shares for ~$118 million during fiscal 2026, and has ~$132 million left on its authorization. What it has not done is earn much: full-year adjusted EBITDA was ~$58 million, a 9.4% margin, and free cash flow was ~$27 million. At about $1.9 billion in market value, the stock prices in a margin recovery that management has promised before. The October deals with Elegen and SynPlexity, plus three North American lab closures, show where the company is placing its bets: gene synthesis grows, and Sanger sequencing shrinks.

The bull case: what would have to be true for $57.00

The most optimistic published target on AZTA is $57.00, +27.2% from the $44.80 share price on November 20, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Margin recovery from cost cuts

The plan for fiscal 2027 depends mainly on costs. Azenta guided adjusted EBITDA margin up 200 to 250 basis points from 9.4%, which implies roughly 11.5% to 12% on ~$648 million to $660 million of revenue, or about $75 million to $79 million of adjusted EBITDA. The October restructuring closes three Multiomics lab sites in North America and is expected to save ~$11 million a year once complete by March 2027, on top of about $7 million from earlier fiscal 2026 actions. Management also guided free cash flow up about 25%. Fourth-quarter adjusted operating margin of 6.9% was up 120 basis points from a year earlier. Peers in life-science tools often run EBITDA margins above 20%, so even the guided level leaves a wide gap to close.

2. Gene synthesis replacing Sanger sequencing

Inside Multiomics, Sanger sequencing is declining as research moves to newer methods, and management said it trims about 4 points from the segment's organic growth and about 2 points from the company's. Fourth-quarter Multiomics revenue was flat at ~$73 million, down 1% organically. Gene synthesis grew, led by China. On October 28 Azenta licensed Elegen's cell-free gene synthesis technology on an exclusive, royalty-free basis (fixed license fees of $23 million, with a $25 million option to make it perpetual) and bought SynPlexity, a pooled gene library company, for $15 million plus up to $10 million in earnouts. Total capital for the Elegen deal is expected to be ~$32 million to $71 million. Management said the deals dilute fiscal 2027 margin by about 100 basis points.

3. Sample storage and repository services

Sample Management Solutions is the larger and steadier segment. Fourth-quarter revenue rose 9% to ~$94 million, or 4% organically, driven by Sample Repository Services and consumables and instruments, and helped by the acquisition of UK Biocentre, which added about 3 points to total company growth in the quarter. Repository contracts tend to be long and recurring, since moving millions of frozen samples is costly and risky for a customer. Automated Stores, the large automated freezer systems, was weaker because of customer capital constraints and quality rework that cost about $6 million in fiscal 2026. Management said bookings improved in the fourth quarter and that two new Automated Stores product lines are planned for the end of fiscal 2027.

4. Cash, buybacks and the next CEO

With ~$506 million in cash and securities and no debt, more than a quarter of Azenta's ~$1.9 billion market value is cash. The company repurchased 4.4 million shares in fiscal 2026, shrinking the count to roughly 43 to 44 million, and has ~$132 million left under a program that runs through 2028. That cash also pays for the Elegen and SynPlexity deals and the restructuring, which is expected to cost about $7 million in cash. Leadership is unsettled: Dr. Madaus has been interim CEO since August 22, 2026, and the earnings call did not update on a permanent search. Management is scheduled to present at the Evercore Healthcare Conference in December. The next CEO's choices on whether to keep both segments, spend cash on acquisitions or buy back more shares will shape the stock as much as quarterly results.

The bear case: what would have to be true for $50.00

The most pessimistic published target is $50.00, +11.6% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Azenta is worth if the risks below bite instead of the drivers above.

Execution is the main risk. Azenta reaffirmed growth and margin targets in February 2026, then cut them in May alongside a $149 million impairment, and the stock fell about 25%. Guidance for fiscal 2027 asks for 3% to 5% organic growth and wider margins at the same time, under an interim CEO. Several law firms, including Rosen and Pomerantz, have announced investigations into possible securities claims tied to the May guidance cut and the August CEO resignation; as of early November 2026 no filed complaint was confirmed, but one could follow. Sanger sequencing keeps shrinking, and gene synthesis is crowded, with Twist Bioscience, IDT (part of Danaher) and GenScript all larger in the market. The Elegen license and SynPlexity purchase are early bets that cut margin first. Automated Stores sales depend on customers' capital budgets and on fixing the quality problems. China drove gene synthesis growth (China revenue rose 23% in fiscal 2026), which exposes the company to US-China trade and biotech policy. Lower NIH and academic funding and slower biotech spending would also weigh on demand. After a ~20% one-day rise and a gain of about 34% over three months, the shares carry high expectations into fiscal 2027, at about 50 times forward EPS estimates of $0.89.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding AZTA already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on AZTA

5 analysts cover AZTA, with an average target of $52.60 (+17.4% against $44.80) and a split of 3 buy, 3 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the AZTA forecast and price target page.

How is AZTA valued?

Market cap, P/E and dividend yield at today's price are in the AZTA key stats above. The business figures below come from Azenta's reported results as of November 2026 and change when it next reports.

  • Revenue (FY2026, continuing ops): ~$622 million (Q4 up ~5%)
  • FY2027 revenue guidance: ~$648M to $660M
  • Adjusted EBITDA margin (FY2026): ~9.4%
  • Gross margin (FY2026): ~44%
  • Cash and securities (Sept. 30, 2026): ~$506 million, no debt
  • Market value (~$44.51 share price): ~$1.9 billion

As of November 2026: At ~$44.51 and roughly 43 to 44 million shares, Azenta's market value is about $1.9 billion, or about $1.4 billion after subtracting cash and securities. That is roughly 2.9 times fiscal 2026 revenue and about 2.2 times the midpoint of fiscal 2027 guidance after cash, and about 50 times the ~$0.89 of EPS analysts expect for fiscal 2027. GAAP results were a loss of $3.50 per share from continuing operations because of the impairment. Before the November report, MarketBeat showed a consensus Hold rating with an average target near $40 to $41; Yahoo Finance's five-analyst consensus now reads Buy with a mean target near $52.60, after Needham moved to $57.

How do you decide if AZTA is a buy?

Whether AZTA is a buy is easier to judge through four narrower questions:

  • Thesis: do you believe the bull case above, and is it still true today?
  • Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
  • Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
  • Overlap: check whether you already hold AZTA indirectly through an index or sector ETF before adding more.

What would change your mind on AZTA

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

  • Bull case breaks if: Margin recovery from cost cuts stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
  • Bear case breaks if: execution is the main risk fails to materialise over several reporting periods while the drivers keep compounding.
  • Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the AZTA stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about AZTA against your real portfolio and see your actual exposure before deciding.

Your questions about Azenta

Ask Walnut's AI anything about AZTA and see how it fits what you own.

FAQ

Is AZTA a good stock to buy right now?

+

That depends on which case you find more convincing, and both are on this page. The bull case rests on Margin recovery from cost cuts, with revenue (fy2026, continuing ops) at ~$622 million (Q4 up ~5%). The bear case rests on execution is the main risk. Analysts covering it are spread from $50.00 to $57.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Should I sell AZTA?

+

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Execution is the main risk. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $50.00, +11.6% from the $44.80 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.

What is the bull case for AZTA?

+

Margin recovery from cost cuts. The plan for fiscal 2027 depends mainly on costs. The most optimistic analyst target on AZTA is $57.00, +27.2% from the $44.80 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for AZTA?

+

Execution is the main risk. Azenta reaffirmed growth and margin targets in February 2026, then cut them in May alongside a $149 million impairment, and the stock fell about 25%. Guidance for fiscal 2027 asks for 3% to 5% organic growth and wider margins at the same time, under an interim CEO. Several law firms, including Rosen and Pomerantz, have announced investigations into possible securities claims tied to the May guidance cut and the August CEO resignation; as of early November 2026 no filed complaint was confirmed, but one could follow. Sanger sequencing keeps shrinking, and gene synthesis is crowded, with Twist Bioscience, IDT (part of Danaher) and GenScript all larger in the market. The Elegen license and SynPlexity purchase are early bets that cut margin first. Automated Stores sales depend on customers' capital budgets and on fixing the quality problems. China drove gene synthesis growth (China revenue rose 23% in fiscal 2026), which exposes the company to US-China trade and biotech policy. Lower NIH and academic funding and slower biotech spending would also weigh on demand. After a ~20% one-day rise and a gain of about 34% over three months, the shares carry high expectations into fiscal 2027, at about 50 times forward EPS estimates of $0.89. The most pessimistic published target is $50.00, +11.6% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.

What does Azenta do?

+

Life-science tools company that stores biological samples for drug makers and runs the GENEWIZ gene sequencing and synthesis business.

What would have to change for AZTA to stop being worth holding?

+

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Margin recovery from cost cuts) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (execution is the main risk) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does Azenta do?

+

Azenta sells tools and services that help drug companies, biotechs, hospitals and research labs store biological samples and analyze DNA. Its Sample Management Solutions segment makes automated freezer systems, cryogenic storage, sample tubes and racks, and runs repositories that hold samples for customers for years. Its Multiomics segment, sold under the GENEWIZ name, sequences DNA and synthesizes genes for researchers. In fiscal 2026, which ended September 30, the two segments brought in about $344 million and $277 million, for ~$622 million in total. Azenta used to be Brooks Automation, and it sold its semiconductor business in 2022 and its B Medical Systems vaccine cold-chain business in July 2026. It is headquartered in Burlington, Massachusetts, and trades on Nasdaq under AZTA.

Why did Azenta stock jump in November 2026?

+

The shares rose about 20% to roughly $48.90 on November 11, 2026, the day after fiscal fourth-quarter results. Adjusted EPS was $0.28, more than double consensus estimates of about $0.11 to $0.12, and revenue of ~$167 million beat the ~$160 million to $163 million expected. Management guided fiscal 2027 revenue to ~$648 million to $660 million, organic growth of 3% to 5%, adjusted EBITDA margin up 200 to 250 basis points, and free cash flow up about 25%. After a year that included a guidance cut, a $149 million impairment and a CEO resignation, investors read the quarter and outlook as evidence the turnaround is starting. The stock had traded below $20 in May 2026. By November 20 the shares had settled near $44.51, still about 22% higher for the month, and Needham lifted its price target to $57 from $37.

Is Azenta being acquired?

+

No acquisition of Azenta has been announced. Its most recent 8-K filings, through November 10, 2026, cover quarterly results, an October restructuring of its Multiomics labs, and two deals in which Azenta was the buyer: an exclusive license of Elegen's gene synthesis technology and the purchase of SynPlexity for $15 million plus up to $10 million in earnouts. Azenta has been a seller as well, completing the sale of B Medical Systems in July 2026 and collecting a related $35 million loan in September. The company has a history of reshaping itself through sales, so takeover speculation comes up from time to time, but there is no filed agreement. Its stock price reflects its own results and guidance, not an offer.

Walnut is informational, not investment advice, and gives no verdict on AZTA. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026. Verify current figures with your broker before acting on them.

The case for and against similar stocks